Conebeam CT: A Paradigm Changing Tool
By Junaid Raja, MD, MSPH, FACP, FAAP | Assistant Professor Vascular and Interventional Radiology |Co-Director Vascular and Interventional Radiology Children’s of Alabama | Director of Human Imaging Core (HUMI) O’Neal Comprehensive Cancer Center | Program Director Integrated Interventional Radiology Residency
Introduction
Vascular and interventional radiology (VIR) sits at the frontier of what is clinically feasible today and what will define care tomorrow. When conventional medical or surgical therapies are limited or carry unacceptable risk, VIR specialists are often called upon to deliver innovative, minimally invasive, image-guided solutions. This ethos traces back to Dr. Charles Dotter, the father of VIR, who famously helped a patient avoid leg amputation through endovascular therapy when no other options existed. Advances in imaging and procedural technology have since dramatically expanded the scope and impact of VIR.
Conebeam CT
Conebeam computed tomography (CBCT), developed more than three decades ago, generates three-dimensional volumetric images using a rotating cone-shaped X-ray beam and a flat-panel detector. The system rotates around a fixed axis while the patient remains stationary, and reconstruction algorithms produce images across multiple planes.
Over the past 10–15 years, CBCT has gained significant traction in interventional settings. It enables geospatial visualization without requiring patient transfer between angiography and CT suites, improving safety while reducing procedure time and room utilization. In many cases, CBCT also reduces cumulative radiation exposure for both patients and operators. As a result, its applications in VIR continue to expand.
Comparing CBCT With Fluoroscopy and MDCT
Fluoroscopy remains the foundational imaging modality in VIR, providing continuous X-ray imaging during contrast injection or device manipulation. However, fluoroscopy is inherently two-dimensional and requires multiple projections to infer depth and spatial relationships, which can be challenging in complex anatomy and may increase procedure time and radiation exposure.
Multidetector CT (MDCT) is widely used for interventions requiring high soft-tissue contrast. It requires patient transport through a gantry and typically involves higher radiation exposure but offers superior soft-tissue resolution. Real-time vascular intervention is limited, although CT fluoroscopy provides narrow real-time axial imaging at a higher cost and radiation burden. Hybrid CT–angiography systems offer combined capabilities but remain expensive, space-intensive, and limited in availability.
CBCT offers a pragmatic middle ground. Compared with fluoroscopy, it provides cross-sectional imaging and improved spatial localization. With contrast enhancement and multiphase acquisitions from a single injection, CBCT can characterize tissue perfusion and vascular supply with greater precision. While unenhanced soft-tissue resolution remains inferior to MDCT, intravascular contrast significantly improves image quality. CBCT also typically requires less space and lower capital investment, with favorable workflow implications.
From a capital and operational perspective, CBCT offers advantages over hybrid angio-CT and MDCT in select scenarios, with lower space requirements and the potential to increase procedural suite capacity and utilization.
Angiographic Guidance
Angiographic CBCT is most widely used in neurointerventions, liver-directed therapies, and prostate arterial embolization (PAE). In neurointerventional procedures, CBCT angiography (CBCTA) enables detailed intracranial vascular mapping for stroke, aneurysm, and arteriovenous malformation treatment, with advanced reconstructions providing intuitive three-dimensional roadmaps for planning.
In liver interventions, CBCTA is increasingly standard for tumor localization, identification of tumor-feeding vessels, assessment of parenchymal perfusion, and detection of occult lesions—capabilities that are critical for radioembolization and transarterial chemoembolization (TACE).
CBCTA is also becoming standard in PAE, where arterial anatomy is highly variable and extra-prostatic embolization must be avoided. CBCTA has improved procedure safety, effectiveness, and efficiency while also improving accessory supply detection.
Vendor-specific vessel detection software can generate GPS-like vascular maps and overlay them in real time to guide catheter navigation. Emerging applications may include angiographic mapping for gastrointestinal hemorrhage and trauma.
Trajectory Planning
Modern CBCT also serves as a navigation platform for percutaneous interventions. Three-dimensional reconstructions enable planning of entry and target points for biopsies, abscess drainage, or tumor ablation. Software tools calculate optimal trajectories to avoid critical structures and determine ideal angles and positioning, which can be overlaid on live fluoroscopy. This capability can reduce procedure time and radiation exposure while improving procedural safety.
Resource Utilization
CBCT’s integration into existing procedural environments is a key operational advantage. Most modern angiography suites and some fluoroscopic C-arm systems support CBCT and CBCTA, although not all institutions deploy the full software suite. In contrast, MDCT and hybrid CT platforms are more resource-intensive, costly, and space-constrained, limiting scalability and throughput.
Limitations
CBCT has several limitations. Optimal imaging requires the target anatomy to be near the center of the rotational axis with sufficient clearance for detector rotation, which can be challenging in larger patients or peripheral anatomy. Spatial resolution for unenhanced soft tissue remains inferior to MDCT, and C-arm detector and motion constraints persist. Software limitations can affect axial localization, although trajectory mapping partially mitigates this.
Further advances in dose optimization, flow characterization, and perfusion modeling would enhance technical decision-making, including embolic agent selection and sizing.
Future Directions
The future of CBCT is promising. Expanded anatomical applications could reduce patient transfers and shorten time to treatment in high-acuity settings. Integration of computational flow and perfusion modeling may enable prediction and monitoring of therapeutic endpoints. Continued improvements in radiation dose reduction, axial localization, laser targeting, and mobile C-arm integration will further broaden clinical utility.
From a capital and operational perspective, CBCT offers advantages over hybrid angio-CT and MDCT in select scenarios, with lower space requirements and the potential to increase procedural suite capacity and utilization. The VIR innovation paradigm is best demonstrated by CBCT, which maximizes therapeutic benefit while using resources efficiently. For healthcare systems, particularly those operating under resource constraints, CBCT represents a powerful tool to improve safety, efficiency, and value in advanced minimally invasive therapies, extending the legacy of innovation pioneered by Dr. Dotter.